Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2891-2898

  Gleave, Martin ^a,b   Tolcher, Anthony ^b   Miyake, Hideaki ^a,b   Nelson, Colleen ^a,b   Brown, Bob ^c   Beraldi, Eliana ^b   Goldie, James ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Genta Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; PROTEIN BCL 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CASTRATION; GENE THERAPY; HORMONAL REGULATION; IMMUNOBLOTTING; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN DETERMINATION; PROTEIN SYNTHESIS REGULATION; RAT; TUMOR GROWTH; TUMOR VOLUME;

ANDROGENS; ANIMALS; APOPTOSIS; CELL DIVISION; HUMANS; MALE; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER;

EID: 0032741282     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Denis, L., and Murphy, G. P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (Phila.), 72 (Suppl): 3888-3895, 1993.
2. Yagoda, A., and Petrylak, D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer (Phila.). 71 (Suppl. 3): 1098-1109, 1993.
3. Isaacs, J. Growth regulation of normal and malignant prostatic cells. First International Consultation on Prostate Cancer. In: Murphy, Griffiths, Denis, Khoury, Chatelain, and Cockett (eds.), Scientific Communication International Ltd., 1996.
4. Gleave, M., Hsieh, J. T., Wu, H. C., von Eschenbach, A. C., and Chung, L. W. Serum prostate-specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 1598-1605, 1992.
5. Hsieh, J., Wu, H., Gleave, M., von Eschenbach, A., and Chung, L. Autocrine regulation of prostate-specific antigen gene expression in human prostate cells. Cancer Res., 53: 2852-2859, 1993.
6. Rennie, P., Bruchovsky, N., Buttyan, R., Benson, M., and Cheng, H. Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res., 48: 6309, 1988.
7. Reed, J. C. bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124; 1-6, 1994.
8. Yang, E., Korsemeyer, S. J. Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood, 88: 386-401, 1996.
9. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334-336, 1990.
10. Nunez, G., London, L., Hockenbery, D., Alexander, M., McKearn, J. P., and Korsmeyer, S. J. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol., 144: 3602-3610, 1990.
11. Tsujimoto, Y. Stress-resistance conferred by a high level of bcl-2 α protein in human B lymphoblastoid cell. Oncogene. 4: 1331-1336, 1989.
12. Miyashita, T., and Reed, J. C. bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81: 151-157, 1993.
13. Kyprianou, N., King, E. D., Bradbury, D., and Rhee, J. G. bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer. 70: 341-348, 1997.
14. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Bauer, J. J. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120: 159-166, 1996.
15. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blochlinger, A., Gasser, T. C., and Mihatsch, M. J. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am. J. Pathol., 148: 1557-1565, 1996.
16. Matsushima, H., Hosaka, Y., Suzuki, M., Mizutani, T., Ishizuka, H., and Kawabe, K. bcl-2 expression on prostate cancer and its relationship to cell cycle and prognosis. Int. J. Urol., 3: 113-117, 1996.
17. McDonnell, T. J., Navone, N. M., Troncoso, P., Pisters, L. L., Conti, C., von Eschenbach, A. C., Brisbay, S., and Logothetis, C. J. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen-independent prostate cancer. J. Urol., 157: 569-574, 1997.
18. Raffo, A. J., Perlman, H., Chen, M. W., Day, M. L., Streitman, J. S., and Buttyan, R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.
19. Saijo, Y., Perlaky, L., Wang, H., and Busch, H. Pharmacokinetics, tissue distribution, and stability of antisense oligonucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res., 6: 243-249, 1994.
20. Crooke, S. T., Lemonidis, K. L., Neilson, L., Griffey, R., Lesnik, E. A., and Monia, B. P. Biochem. J., 312: 599-608, 1995.
21. Cleave, M. E., Hsieh, J. T., Gao, C., von Eschenbach, A. C., and Chung, L. W. K. Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51: 3753-3761, 1991.
22. Sato, N., Gleave, M. E., Bruchovsky, N., Rennie, P. S., Goldenberg, S. L., Lange, P. L., and Sullivan, L. D. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J. Steroid Biochem. Mol. Biol., 58: 139-146, 1996.
23. Liu, A., Grey, E., Bladou, F., Lange, P., and Vessella, R. Prostatic cell lineage markers: emergence of bcl2 cells of human prostate cancer xenograft LuCaP 23 following castration. Int. J. Cancer, 65: 85-89, 1996.
24. Sellins, K., and Cohen, J. Gene induction by γ irradiation leads to DNA fragmentation in lymphocytes. J. Immunol., 39: 3199-3206, 1987.
25. Gleave, M. E., Sato, N., Rennie, P., and Bruchovsky, N. Prevention of LNCaP prostate tumor growth and progression by isobutyratnide, and orally bioavailable butyrate analogue. J. Cell. Biochem., 69: 271-281, 1998.
26. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med., 2: 668-675, 1996.
27. Horoszewicz, J., Leong, S., Chu, T., Wajsman, Z., Friedman, M., Papsidero, L., Kim, U., Chai, L. S., Kakati, S., Arya, S. K., and Sandberg, A. A. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res., 37: 115-132, 1980.
28. Sato, N., Satar, M., Bruchovsky, N., Rennie, P., Saatcioglu, F., Sato, S., Lange, P., and Gleave, M. Androgenic induction of prostate-specific gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-jun in the human prostate cancer cell line LNCaP. J. Biol. Chem., 272: 17485-17494, 1997.
29. Ziegler, A., Luedke, G. H., Fabbro, D., Altmann, K-H., Stahel, R. A., and Zangemeister-Wittke, U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst., 89: 1027-1035, 1997.
30. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichler, H-G., and Pehamberger, H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998.
31. Dorai, T., Olsson, C. A., Katz, A. E., and Buttyan, R. Development of a hammerhead ribozyme against bcl-2. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate, 32: 246-258, 1997.
32. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. bcl-2 antisense therapy in patients' with non-Hodgkin's lymphoma. Lancet. 349: 1137-1141, 1997.
33. Miyake, H., Tolcher, A., Gleave, M. E. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen independence after castration in the shionogi tumor model. Cancer Res., 59: 4030-4034, 1999.
34. Stein, C. A., and Cheng, Y-C. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science (Washington, DC), 267; 1004-1012, 1993.
35. Stein, C. A. Does antisense exist? Nat. Med., 1: 1119-1121, 1995.
36. Wooldridge, J. E., Ballas, Z., Krieg, A. M., and Weiner, G. J. Immunostimulatory oligonucleotides containing CpG motifs enhance the efficacy of monoclonal therapy of lymphoma. Blood, 89: 2994-2998, 1997.
37. Crooke, S. T., Lemonidis, K. L., Neilson, L., Griffey, R., Lesnik, E. A., and Monia, B. P. Kinetic characteristics of Escherichia coli RNase HI: cleavage of various antisense oligonucleotide-RNA duplexes. Bioehem. J., 312: 599-608, 1995.
38. Gao, W. Y., Han, F-S., Storm, C., Egan, W., and Cheng, Y. C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerase and RNase H: implications for antisense technology. Mol. Pharmacol., 41: 223-230, 1991.
39. Guvakova, M. A., Yakubov, L. A., Vlodabsky, I., Tonkinson, J. L., and Stein, C. A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem., 270: 2620-2627, 1994.
40. Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M., and Lawson, D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 50: 2275-2282, 1990.
41. Hoehn, W., Schroeder, F., Riemann, J., Joebsis, A., and Hermanek, P. Human prostatic adenocarcinoma. Some characteristics of a serially transplantable line in nude mice (PC-82). Prostate, 1: 95, 1980.
42. Oberhammer, F., Wilson, J. W., Dive, C., Morris, I. D., Hickman, J. A., Wakeling, A. E., Walker, P. R., and Sikorska, M. Apoptotic death in epithelial cells; cleavage of DNA to 300 and/or 50-kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J., 12: 3679-3684, 1993.